Primary cutaneous aspergillosis in a patient with a solid organ transplant: case report and review of the literature.
OBJECTIVE
To understand primary cutaneous aspergillosis to better manage patients with the condition.


OBJECTIVE
Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Describe risk factors for Aspergillus infection. 2. Identify diagnostic methods for primary cutaneous aspergillosis. 3. Discuss treatment options for primary cutaneous aspergillosis. Primary cutaneous aspergillosis is an uncommon disease in immunocompetent individuals that often affects immunosuppressed hosts. We present the first reported case of primary cutaneous aspergillosis in a solid organ transplant recipient caused by Aspergillus niger. Fruiting bodies were isolated from a necrotic ulcer arising in a surgical wound. Debridement alone failed to resolve the infection, emphasizing the need for early antifungal treatment combined with surgical management of this infection.
Thomas
Lacey M
LM
Department of Dermatology, Vanderbilt University Medical Center, The Vanderbilt Clinic, Nashville, TN 37232, USA. lacey.m.thomas@vanderbilt.edu
Rand
Heidi K
HK
Miller
Jami L
JL
Boyd
Alan S
AS
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D003646:Debridement; D003937:Diagnosis, Differential; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008875:Middle Aged; D013530:Surgical Wound Infection / Q000276:immunology / Q000382:microbiology* / Q000628:therapy
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D000666:Amphotericin B